A networked swellable dextrin nanogels loading Bcl2 siRNA for melanoma tumor therapy

被引:0
|
作者
Huipeng Li
Zhanwei Zhou
Feiran Zhang
Yuxin Guo
Xue Yang
Hulin Jiang
Fei Tan
David Oupicky
Minjie Sun
机构
[1] China Pharmaceutical University,State Key Laboratory of Natural Medicines and Department of Pharmaceutics
[2] University of Nebraska Medical Center,Center for Drug Delivery and Nanomedicine, Department of Pharmaceutical Sciences
[3] Skin Disease Hospital of Tongji University,Shanghai Skin Disease Hospital
来源
Nano Research | 2018年 / 11卷
关键词
dextrin nanogels; local enrichment; reduction-responsive; lysosomal escape; disulfide cross-linked; small interfering RNA (siRNA) delivery;
D O I
暂无
中图分类号
学科分类号
摘要
In this study, a networked swellable dextrin nanogel (DNG) was developed to achieve stimulated responsive small interfering RNA (siRNA) release for melanoma tumor therapy. siRNA was loaded into multidimensional dextrin nanogels by charge condensation with positive arginine residues modified in the dextrin backbone. Moreover, the networked nanogel was destroyed and loosened based on its bioreducible responsive property to control accelerated siRNA release in a bioreducible intracellular environment, while it remained stable under normal physiological conditions. We demonstrated that DNGs had swellable and disassembly properties under reduced buffer condition by transmission electron microscopy evaluation. The DNGs achieved an endosomal escape followed by selective release of the cargo into the cytosol by glutathione-triggered disassembly according to confocal microscopy observation. Thus, this smart nanogel achieved outstanding luciferase gene silencing efficiency and decreased Bcl2 protein expression in vitro and in vivo based on western blot analysis. Moreover, this nanogel exhibited superior anti-tumor activity for B16F10 xenograft tumors in C57BL/6 mice. These results demonstrate that the networked DNGs are effective for gene condensation and controlled intracellular release for tumor therapy. Overall, these findings suggest that this multidimensional swellable stimuli-responsive dextrin nanogel is an innovative strategy with great promise for gene and drug delivery.
引用
收藏
页码:4627 / 4642
页数:15
相关论文
共 50 条
  • [21] Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types
    Ben-Hamo, Rotem
    Zilberberg, Alona
    Cohen, Helit
    Bahar-Shany, Keren
    Wachtel, Chaim
    Korach, Jacob
    Aviel-Ronen, Sarit
    Barshack, Iris
    Barash, Danny
    Levanon, Keren
    Efroni, Sol
    NPJ PRECISION ONCOLOGY, 2019, 3 (1)
  • [22] Resistance to paclitaxel is associated with a variant of the gene BCL2 in multiple tumor types
    Rotem Ben-Hamo
    Alona Zilberberg
    Helit Cohen
    Keren Bahar-Shany
    Chaim Wachtel
    Jacob Korach
    Sarit Aviel-Ronen
    Iris Barshack
    Danny Barash
    Keren Levanon
    Sol Efroni
    npj Precision Oncology, 3
  • [23] The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
    Vogler, Meike
    Braun, Yannick
    Smith, Victoria M.
    Westhoff, Mike-Andrew
    Pereira, Raquel S.
    Pieper, Nadja M.
    Anders, Marius
    Callens, Manon
    Vervliet, Tim
    Abbas, Maha
    Macip, Salvador
    Schmid, Ralf
    Bultynck, Geert
    Dyer, Martin J. S.
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [24] Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma
    Mukherjee, Nabanita
    Amato, Carol M.
    Skees, Jenette
    Todd, Kaleb J.
    Lambert, Karoline A.
    Robinson, William A.
    Van Gulick, Robert
    Weight, Ryan M.
    Dart, Chiara R.
    Tobin, Richard P.
    McCarter, Martin D.
    Fujita, Mayumi
    Norris, David A.
    Shellman, Yiqun G.
    CANCERS, 2020, 12 (08) : 1 - 16
  • [25] β-Glucan-Mediated Oral Codelivery of 5FU and Bcl2 siRNA Attenuates Stomach Cancer
    Afrin, Humayra
    Esquivel, Stephanie Vargas
    Kumar, Raj
    Zahid, Md Ikhtiar
    Oporeza, Beu
    Rahman, Md Fashiar
    Boland, Thomas
    Nurunnabi, Md
    ACS APPLIED MATERIALS & INTERFACES, 2023, 15 (27) : 32188 - 32200
  • [26] Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability
    McGill, GG
    Horstmann, M
    Widlund, HR
    Du, JY
    Motyckova, G
    Nishimura, EK
    Lin, YL
    Ramaswamy, S
    Avery, W
    Ding, HF
    Jordan, SA
    Jackson, IJ
    Korsmeyer, SJ
    Golub, TR
    Fisher, DE
    CELL, 2002, 109 (06) : 707 - 718
  • [27] Targeting glucose and glutamine regulated BCL2 family members for multiple myeloma therapy
    Bajpai, Richa
    Matulis, Shannon M.
    Wei, Changyong
    Nooka, Ajay K.
    Boise, Lawrence H.
    Shanmugam, Mala
    CANCER RESEARCH, 2015, 75
  • [28] Ibrutinib therapy increases BCL2 dependence and enhances sensitivity to venetoclax in CLL patients
    Deng, Jing
    Isik, Elif
    Fernandes, Stacey
    Brown, Jennifer R.
    Letai, Anthony
    Davids, Matthew
    LEUKEMIA & LYMPHOMA, 2015, 56 : 96 - 97
  • [29] SIMULTANEOUS SIRNA-MEDIATED INHIBITION OF THE ANTIAPOPTOTIC FACTORS BCL2, BCL2L1, BIRC5 AND XIAP IN BLADDER CANCER CELLS
    Kunze, D.
    Kraemer, K.
    Fuessel, S.
    Grimm, M. O.
    Wirth, M. P.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 78 - 79
  • [30] Immunostimulatory bcl2-specific 5#-triphosphate-siRNA:: combining RIG-Iactivation and gene silencing activity for the therapy of melanoma
    Poeck, H.
    Maihoefer, C.
    Pesch, R.
    Tormo, D.
    Prinz, M.
    Wolter, K.
    Kato, H.
    Akira, S.
    Hornung, V.
    Endres, S.
    Hartmann, G.
    Tueting, T.
    EXPERIMENTAL DERMATOLOGY, 2008, 17 (03) : 275 - 275